Back to top
more

Biogen (BIIB)

(Delayed Data from NSDQ)

$173.04 USD

173.04
1,581,725

-0.88 (-0.51%)

Updated Nov 8, 2024 04:00 PM ET

After-Market: $173.02 -0.02 (-0.01%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value C Growth D Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 31% (77 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks News

Top Ranked Momentum Stocks to Buy for July 31st

Here are three stocks with buy rank and strong momentum characteristics for investors to consider today, July 31st.

3 Reasons Growth Investors Will Love Biogen (BIIB)

Biogen (BIIB) could produce exceptional returns because of its solid growth attributes.

Zacks.com featured highlights include: PepsiCo, T. Rowe Price, Biogen, Lockheed Martin and Northrop Grumman

Zacks.com featured highlights include: PepsiCo, T. Rowe Price, Biogen, Lockheed Martin and Northrop Grumman

Alkermes (ALKS) Earnings and Sales Beat Estimates in Q2

Alkermes (ALKS) surpasses earnings and sales estimates in the second quarter of 2019.

Supriyo Bose headshot

Top 5 ROE Stocks to Buy as Dovish Fed Stance Spurs Volatility

ROE is often used to compare the profitability of a company with other firms in the industry - the higher, the better.

Mark Vickery headshot

Top Analyst Reports for Texas Instruments, Blackstone & Northrop Grumman

Today's Research Daily features new research reports on 16 major stocks, including Texas Instruments (TXN), Blackstone (BX) and Northrop Grumman (NOC).

Biotech Stock Roundup: BIIB Q2 Earnings Top & CELG's Otezla Label Expanded

Key highlights of the past week include earnings update, collaborations and other pipeline news.

Biogen (BIIB) Up on Q2 Earnings & Sales Beat, Raised View

Biogen (BIIB) reports encouraging second-quarter results. Shares rise in pre-market trading.

Biogen (BIIB) Q2 Earnings & Sales Beat Estimates

Biogen (BIIB) beats estimates for both earnings and sales in the second quarter. It lifts sales and earnings expectations for the year. Shares rise in pre-market trading

Can Biogen (BIIB) Keep the Earnings Streak Alive in Q2?

While sales of Biogen's (BIIB) MS franchise are expected to decline in the second quarter of 2019, Spinraza U.S. sales may improve.

Biogen (BIIB) Reports Next Week: Wall Street Expects Earnings Growth

Biogen (BIIB) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Amgen & Novartis' Alzheimer Studies End in Another Failure

Amgen (AMGN) and Novartis (NVS) discontinue two Alzheimer's disease studies. Alzheimer's has always been a highly challenging area with many studies failing.

Nilanjan Banerjee headshot

Will Patent Woes Boost Pharma Stock Megamergers Further?

With key drugs losing exclusivity, key drug makers are poised to face deep trouble since their sales are mostly dependent on a single drug.

Mark Vickery headshot

Top Analyst Reports for Boeing, 3M & U.S. Bancorp

Today's Research Daily features new research reports on 16 major stocks, including Boeing (BA), 3M (MMM) and U.S. Bancorp (USB).

Will Biogen (BIIB) Beat Estimates Again in Its Next Earnings Report?

Biogen (BIIB) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Atara Reports Initial Data for Multiple Sclerosis Candidate

Atara (ATRA) announces initial ATA188 phase I safety results for patients with progressive MS.

Supriyo Bose headshot

5 ROE Stocks to Buy as Trade Talks Resume Ahead of G20 Summit

ROE is often used to compare the profitability of a company with other firms in the industry - the higher, the better.

3 Reasons Why Growth Investors Shouldn't Overlook Biogen (BIIB)

Biogen (BIIB) is well positioned to outperform the market, as it exhibits above-average growth in financials.

The Zacks Analyst Blog Highlights: Union Pacific, NextEra, Biogen, Humana and Marathon

The Zacks Analyst Blog Highlights: Union Pacific, NextEra, Biogen, Humana and Marathon

Mark Vickery headshot

Top Stock Reports for Union Pacific, NextEra & Biogen

Today's Research Daily features new research reports on 16 major stocks, including Union Pacific (UNP), NextEra (NEE) and Biogen (BIIB).

AstraZeneca Gives Detailed Data From Calquence Leukemia Study

AstraZeneca's (AZN) Calquence monotherapy prolongs progression-free survival significantly in relapsed or refractory CLL patients compared to Roche's Rituxan.

Biogen (BIIB) Gains But Lags Market: What You Should Know

Biogen (BIIB) closed the most recent trading day at $230.86, moving +0.19% from the previous trading session.

Biotech Stock Roundup: Celgene Submits MS Drug to FDA, INSY & CBAY Crash

Key highlights of the past week include regulatory approvals, collaborations and pipeline updates.

Biogen (BIIB) Outpaces Stock Market Gains: What You Should Know

Biogen (BIIB) closed the most recent trading day at $227.33, moving +1.33% from the previous trading session.

Celgene's Filing for Ozanimod Accepted for Review in US/EU

The FDA and the EMA accept Celgene's (CELG) multiple sclerosis candidate, ozanimod, for review.